To evaluate the relevance of Vhl gene loss in ICB therapy, we conducted anti-programmed death 1 (αPD1) therapy in several Vhl-deficient tumor lines following the schedule depicted in Figure S1D. In the murine RCC Renca tumor model, VHL loss alone suppressed tumor growth (Figures S1A and 1A). Here, VHL is linked to renal cell adenocarcinoma.